Olokizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
1007223-17-7  |
| ChemSpider | none |
| UNII |
PAI71R1D2W |
 (what is this?) (verify) | |
Olokizumab is an immunomodulator. It binds to interleukin 6.[1] Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA).
It had promising results in a phase II trial against placebo or tocilizumab for patients with moderate to severe RA.[2][3]
References
- ↑ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
- ↑ Another IL-6 Blocker in RA
- ↑ Genovese, MC (2014). "Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study". Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204760. Retrieved 21 February 2016.
This article is issued from Wikipedia - version of the 11/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.